IL18 and autoimmune polyendocrinopathy: OICR‐9429, the epigenetic inhibitor of H3K4me3, ameliorated the secretory IL‐18, IL‐1β and TF, demonstrating the inhibitive function for inflammation and thrombosis in mice with APS and a prospective area of investigation for APS therapy.